Fig. 4

Effect of EGF and/or cetuximab treatment on EGFR, MAPK and AKT activation in MKN1 cells. EGFR, MAPK and AKT activation were detected in total lysates of EGF- and/or cetuximab-treated cells by Western blot analysis using phospho-specific antibodies. Each membrane was probed with antibodies specific for a pEGFR (Y1068), c pAKT (S473) and α-tubulin (loading control). Each blot was then stripped and re-probed with an antibody specific for b pMAPK (T202/Y204). One representative Western blot analysis for each stimulation period is shown. The depicted results are representative of three independent experiments. The average phosphorylation levels were quantified using densitometric analysis and calculated in relation to the levels of α-tubulin (+SD). Statistical p-values are listed in Additional file 1: Table S5. Additionally, one representative Western blot of each stimulation period is shown. Abbreviation: Cet = cetuximab